SCHEMBL1366822

SCHEMBL1366822

Cc1nc(-c2ccccc2)ncc1C(=O)NC1CCN(Cc2ccccn2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD4 P21917 2/20 0.60
SIGMAR1 Q99720 1/20 0.52
CHRM2 P08172 2/20 0.50
CHRM1 P11229 2/20 0.50
CHRM3 P20309 2/20 0.50
L3MBTL1 Q9Y468 1/20 0.49
POLB P06746 2/20 0.48
KDM4E B2RXH2 3/20 0.47
CYP2D6 P10635 1/20 0.47
CYP2C19 P33261 1/20 0.47
DGAT1 O75907 1/20 0.46
PRKAB2 O43741 1/20 0.46
PRKAG1 P54619 1/20 0.46
PRKAA2 P54646 1/20 0.46
PRKAA1 Q13131 1/20 0.46
PRKAG3 Q9UGI9 1/20 0.46
PRKAG2 Q9UGJ0 1/20 0.46
PRKAB1 Q9Y478 1/20 0.46
ALDH1A1 P00352 2/20 0.46
MAPT P10636 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1367633 0.90 DRD4 (0.61) DRD4SIGMAR1CHRM2CHRM1CHRM3
SCHEMBL1365048 0.89 DRD4 (0.60) DRD4SIGMAR1CHRM2CHRM1CHRM3
SCHEMBL1366388 0.88 POLB (0.63) DRD4SIGMAR1POLBCYP2D6CYP2C19
SCHEMBL1367196 0.85 DRD4 (0.67) DRD4SIGMAR1CHRM2CHRM1CHRM3
SCHEMBL1364923 0.83 DGAT1 (0.53) KDM4EDGAT1PRKAA1ALDH1A1MAPK1
SCHEMBL14094525 0.83 DGAT1 (0.53) POLBKDM4EDGAT1ALDH1A1SMN1; SMN2
SCHEMBL1366703 0.80 DGAT1 (0.55) POLBDGAT1SMN1; SMN2
SCHEMBL1367559 0.80 DGAT1 (0.51) DRD4CYP2D6DGAT1ALDH1A1
SCHEMBL12142291 0.80 DRD4 (0.69) DRD4SIGMAR1CHRM2CHRM1CHRM3
SCHEMBL4406616 0.80 KDM4E (0.58) CHRM2CHRM3L3MBTL1KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8067589-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2011-11-29 US disclosed
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions BLAKE TANISHA D 2009-11-12 US disclosed
US-7582643-B2 Heterocyclic compounds useful in treating diseases and conditions PFIZER INC (US) 2009-09-01 US disclosed
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions BLAKE TANISHA D 2008-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281125-A1 Heterocyclic Compounds Useful in Treating Diseases and Conditions CYP11B2, CYP11B1, LTC4S DRD4 4232/4885SIGMAR1 2465/4885CHRM2 872/4885
US-20080207651-A1 Heterocyclic compounds useful in treating diseases and conditions CYP11B2, CYP11B1, LTC4S DRD4 4232/4885SIGMAR1 2465/4885CHRM2 872/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.